Foamix Pharmaceuticals to Release Fiscal Year 2016 Financial Results and Host Conference Call & Webcast on Wednesday, February 22

REHOVOT, Israel, and BRIDGEWATER, New Jersey, Feb. 7, 2017

Conference Call & Webcast

Wednesday, February 22nd  @ 8:30am Eastern Time

Toll Free:                     888-278-8446

International:               913-312-1473

Conference ID:            6799077 ARIVA.DE Börsen-Geflüster Kurse Foamix Pharmaceut -   0,00%

Webcast:                    http://public.viavid.com/index.php?id=122682

Replays, through March 8th:

Toll-Free:                     844-512-2921

International:               412-317-6671

Conference ID:            6799077

About Foamix Pharmaceuticals Ltd.

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.

Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare and others.

For more information, please visit www.foamixpharma.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/foamix-pharmaceuticals-to-release-fiscal-year-2016-financial-results-and-host-conference-call--webcast-on-wednesday-february-22-300403661.html

SOURCE Foamix Pharmaceuticals Ltd.